دورية أكاديمية
أعرض في EDS

In Vivo Bioluminescence Imaging Reveals Differences in Leishmania infantum Parasite Killing Kinetics by Antileishmanial Reference Drugs.

التفاصيل البيبلوغرافية
العنوان: In Vivo Bioluminescence Imaging Reveals Differences in Leishmania infantum Parasite Killing Kinetics by Antileishmanial Reference Drugs.
المؤلفون: Hendrickx S; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Feijens PB; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Escudié F; Drugs for Neglected Diseases initiative, 1202 Geneva, Switzerland., Chatelain E; Drugs for Neglected Diseases initiative, 1202 Geneva, Switzerland., Maes L; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Caljon G; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium.
المصدر: ACS infectious diseases [ACS Infect Dis] 2024 Jun 14; Vol. 10 (6), pp. 2101-2107. Date of Electronic Publication: 2024 May 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: ACS Publications Country of Publication: United States NLM ID: 101654580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2373-8227 (Electronic) Linking ISSN: 23738227 NLM ISO Abbreviation: ACS Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : ACS Publications, [2015]-
مواضيع طبية MeSH: Leishmania infantum*/drug effects , Antiprotozoal Agents*/pharmacology , Antiprotozoal Agents*/pharmacokinetics , Mice, Inbred BALB C* , Leishmaniasis, Visceral*/drug therapy , Leishmaniasis, Visceral*/parasitology , Luminescent Measurements*, Animals ; Mice ; Female ; Liver/parasitology ; Liver/drug effects ; Bone Marrow/parasitology ; Bone Marrow/drug effects ; Kinetics ; Disease Models, Animal
مستخلص: The bioluminescent Leishmania infantum BALB/c mouse model was used to evaluate the parasiticidal drug action kinetics of the reference drugs miltefosine, paromomycin, sodium stibogluconate, and liposomal amphotericin B. Infected mice were treated for 5 days starting from 7 days post-infection, and parasite burdens were monitored over time via bioluminescence imaging (BLI). Using nonlinear regression analyses of the BLI signal, the parasite elimination half-life ( t 1/2 ) in the liver, bone marrow, and whole body was determined and compared for the different treatment regimens. Significant differences in parasiticidal kinetics were recorded. A single intravenous dose of 0.5 mg/kg liposomal amphotericin B was the fastest acting with a t 1/2 of less than 1 day. Intraperitoneal injection of paromomycin at 320 mg/kg for 5 days proved to be the slowest with a t 1/2 of about 5 days in the liver and 16 days in the bone marrow. To conclude, evaluation of the cidal kinetics of the different antileishmanial reference drugs revealed striking differences in their parasite elimination half-lives. This BLI approach also enables an in-depth pharmacodynamic comparison between novel drug leads and may constitute an essential tool for the design of potential drug combinations.
References: J Infect Dis. 2024 Jul 25;230(1):183-187. (PMID: 39052713)
Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32601168)
PLoS Negl Trop Dis. 2010 Oct 26;4(10):e709. (PMID: 21049059)
BMJ. 2019 Jan 22;364:k5224. (PMID: 30670453)
J Med Chem. 2021 Nov 11;64(21):16159-16176. (PMID: 34711050)
Int J Parasitol Drugs Drug Resist. 2020 Aug;13:16-21. (PMID: 32388220)
Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):473-5. (PMID: 9373659)
J Infect Dis. 1993 Sep;168(3):715-20. (PMID: 8394861)
J Microbiol Methods. 2013 Dec;95(3):320-3. (PMID: 24055386)
J Antimicrob Chemother. 2017 Feb;72(2):428-430. (PMID: 27707992)
Cell Microbiol. 2005 Mar;7(3):383-92. (PMID: 15679841)
PLoS Negl Trop Dis. 2021 Jul 22;15(7):e0009622. (PMID: 34292975)
J Antimicrob Chemother. 2019 Feb 1;74(2):395-406. (PMID: 30412253)
PLoS Negl Trop Dis. 2015 Feb 13;9(2):e0003556. (PMID: 25679212)
PLoS Negl Trop Dis. 2010 Oct 26;4(10):e855. (PMID: 21049063)
Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):81-86. (PMID: 29425734)
Parasitol Res. 2013 Mar;112(3):1001-9. (PMID: 23242321)
PLoS Negl Trop Dis. 2012;6(6):e1674. (PMID: 22724029)
Pharmaceutics. 2022 Dec 28;15(1):. (PMID: 36678729)
PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007133. (PMID: 30763330)
Commun Biol. 2022 Jun 25;5(1):626. (PMID: 35752645)
Eur J Dermatol. 2005 Mar-Apr;15(2):85-7. (PMID: 15757817)
N Engl J Med. 2007 Jun 21;356(25):2571-81. (PMID: 17582067)
Sci Rep. 2020 Mar 13;10(1):4689. (PMID: 32170135)
Expert Opin Investig Drugs. 2008 May;17(5):787-94. (PMID: 18447603)
Am J Trop Med Hyg. 2007 Jun;76(6):1128-31. (PMID: 17556623)
Nat Rev Microbiol. 2023 Jan;21(1):35-50. (PMID: 35995950)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: BLI; Leishmania; TTK; bioluminescence; pharmacodynamics
المشرفين على المادة: 0 (Antiprotozoal Agents)
تواريخ الأحداث: Date Created: 20240511 Date Completed: 20240614 Latest Revision: 20240927
رمز التحديث: 20240927
مُعرف محوري في PubMed: PMC11423396
DOI: 10.1021/acsinfecdis.4c00109
PMID: 38733389
قاعدة البيانات: MEDLINE
الوصف
تدمد:2373-8227
DOI:10.1021/acsinfecdis.4c00109